Venlafaxine Hydrochloride Extended-Release Capsules 150 mg,Efexor XR 150 mg Capsules
Sponsors
Bio-innova Co., Ltd.
Conditions
Healthy subjects
Bioequivalence Venlafaxine Hydrochloride Extended-Release Capsules 150 mg
Phase 1
A randomized, open-labeled, multiple-dose, two-way crossover design with two-period, two-treatment, two-sequence steady-state bioequivalence study of Venlafaxine Hydrochloride Extended-Release Capsules 150 mg and Efexor XR 150 mg Capsules in healthy, adult, Thai volunteers under fed condition
TCTR20240706012
Start: 2025-05-20Target: 44Updated: 2026-08-03
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment, and two-sequence of Venlafaxine Hydrochloride Extended-Release Capsules 150 mg and Efexor XR 150 mg Capsules in healthy, adult, Thai volunteers under fed condition
TCTR20240706010
Start: 2025-05-13Target: 36Updated: 2026-08-03